FHTX Q4 2021 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$713,000+184.1% YoY

Gross Profit

-$22M-3050.5% margin

Operating Income

-$28M-3938.6% margin

Net Income

-$29M-4087.4% margin

EPS (Diluted)

$4.62

QoQ Revenue Growth

+1639.0%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$520M

Total Liabilities

$423M

Stockholders' Equity

$97M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$713,000	$251,000	+184.1%
Gross Profit	-$22M	-$312,000	-6871.2%
Operating Income	-$28M	-$21M	-35.1%
Net Income	-$29M	-$21M	-40.4%